Trial Profile

A Phase I Study on Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GC-203-TIL (Primary)
Indications Ovarian cancer; Solid tumours
Focus Adverse reactions
Acronyms KUNLUN-001
Sponsors Shanghai Juncell Therapeutics

Most Recent Events

18 Dec 2024 According to a Shanghai Juncell Therapeutics, Phase I clinical trial is anticipated to be launched in 2027.
24 May 2024 Status changed from not yet recruiting to recruiting.
24 May 2024 According to a Shanghai Juncell Therapeutics, data will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place on May 31 - June 4, 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com